Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Tumour models London 1-3 December 2015 Agenda

Tumour Models London 2015, now in its 4th year,is the leading meeting dedicated to improve preclinical predictability and translational success of oncology discoveries. Tackling clinical failures rates, preclinical strategies and translational challenges, this Summit will enable you to translate your discoveries from model to human studies with superior predictability to future proof clinical success. [Read More…]

  • Be the first to comment

  • Be the first to like this

Tumour models London 1-3 December 2015 Agenda

  1. 1. Christian Gerdes Head of Pharmacology, Roche Pharma Research & Early Development Roche Innovation Center Zürich 17 Expert Speakers Include: Jürgen Moll Director Pharmacology & Translational Research Boehringer-Ingelheim Sukhvinder Sidhu Head of Pharmacology, Oncology Drug Discovery & Preclinical Development Sanofi Giovanni Di Veroli Associate Director of Systems Pharmacology AstraZeneca Marie Dutreix Director of Research Institut Curie Harness the Latest Humanized, Syngeneic, PDX & Ex Vivo Models to: • Enhance Validation & Lead Optimisation of Discoveries • Improve Preclinical Predictions & Translational Decisions • Ensure Clinical Success & Enhanced Patient Outcomes 1-3 December 2015 LONDON, UK Lead Partner: Additional Partners: Tel: +44 (0)20 3141 8700 | Email: info@hansonwade.com www.tumour-models.com RESEARCHED & DEVELOPED BY: Tumor Models @Tumor_Models Book now and save up to £500 4th Annual
  2. 2. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK Welcome Back to Tumour Models London 2015 Tumour Models London 2015, now in its 4th year,is the leading meeting dedicated to improve preclinical predictability and translational success of oncology discoveries. Tackling clinical failures rates, preclinical strategies and translational challenges, this Summit will enable you to translate your discoveries from model to human studies with superior predictability to future proof clinical success. With the explosion of cancer immunotherapies and combination therapies, the 4th Tumour Models London Summit will bring together scientific leaders from pharma, biotech and academia, who will equip you to advance therapies through innovative in vitro, in vivo and ex vivo models. Discover the innovative ways the industry is developing humanized mice and the preclinical data being generated to advance immunotherapies across the translational gap. With the field poised for success, optimise your preclinical strategies to accelerate your understanding of your drug candidates by making faster strategic decisions. Tumour Models London will detail the latest work and case studies from those striving to create a step-change in improving preclinical predictability and translational success. 2. Learn how ex vivo models are being utilised   to mimic the tumour microenvironment 2.Discover how the industry are developing humanized mice models for routine use in preclinical trials 5 Key Benefits to Takeaway 1.Discover how syngeneic models are optimising preclinical predictions for the development cancer immunotherapies 1.Enhance your current preclinical strategies to better predict the clinical outcomes of your drug candidates 3.Uncover and interpret early clinical data to better understand the preclinical predictions generated from PDX models 3.Harness the immuno-competent models being applied for the development of cancer immunotherapies 4.Discover the strategies being applied to develop combination therapies to overcome resistance mechanisms 4.Capture how PDX models are optimising preclinical predictions through reverse- translation 5.Understand the latest developments in optimising metastasis models to capture the heterogeneous patient population 5.Optimise your data interpretation from preclinical studies to enhance the clinical success of your drug candidates 5 Key Ideas to Implement Increase Speed and Efficiency of Progressing Your Most Promising Drug Candidates Across the Translational Gap
  3. 3. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK Speakers SEARCH GROUPS FOR:   Tumor Models London 2015 to join the online community. Andrew McKenzie Director, Scientific Operations Michael Lisanti Director, Breast Cancer Now Research Unit, Institute of Cancer Sciences Giovanni Di Veroli Associate Director of Systems Pharmacology Marie Dutreix Director of Research Kelli Ryan Senior Scientist Julie Stock Preclinical RaDCom Project Manager Neal Goodwin VP, Corporate Research Development Adam O’Shea Scientist Sophia Karagiannis Senior Lecturer in Translational Cancer Immunology, Head of Cancer Antibody Discovery Immunotherapy Brian Soper Technical Information Scientist Bruno Gomes Senior Project Leader Society Anne Chessex Senior Scientific Officer, Pharmacology Screening Christian Gerdes Head of Pharmacology, Roche Pharma Research Early Development Jürgen Moll, Director Pharmacology Translational Research Sukhvinder Sidhu Head of Pharmacology, Oncology Drug Discovery Preclinical Development Christoph Schatz Senior Scientist Mustafa Djamgoz Professor of Cancer Biology Excellent conference, very good balance of presentation between suppliers, academics, large pharma and biotech. The quality of talks was good and the informal networking was very useful Past Tumour Models London attendee, e-Therapeutics plc
  4. 4. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK Workshop A This interactive workshop will give you the chance to learn from a highly experienced senior scientist and other leading researchers within the field of cancer immunotherapy and the current developments of immuno-competent models. Key takeaway and questions to be addressed include: • Exploring the different strategies of immune system humanization in mice • How predictive are the humanized mouse models (predictive validity, efficacy/ safety/biomarkers)? • Exploring humanized models to select combinations of immunotherapies • Discussing the further improvements required and how other models could support them Bruno Gomes has more than ten years of experience in pharmaceutical companies as a in vivo study director in oncology, head of in vivo oncology, and finally a senior project leader in immunotherapies. He has developed strong expertise in oncology, immunology and the drug development process, leading preclinical programs with kinase inhibitors and onco-immunology drugs. He has been focusing on increasing the translational relevance of preclinical models (including syngeneic tumour models in mice, xenografts and PDX tumour models in mice, humanized mice models and spontaneous canine tumours). Workshop leader Bruno Gomes Senior Project Leader Society iTeos Therapeutics Is Using Mice in an Humanized Immune System Really Improving the Clinical Translation of New Immunotherapies? Tuesday 1st December 2015 | Time: 9.00-12.00 A structured networking session - run like speed dating- especially designed to facilitate quick introductions to the majority of attendees within the preclinical oncology field. Use the time wisely to meet new contacts, reconnect with old friends and identify those you want to spend more time with. Take part in facilitated discussion sessions focused around specific, high priority issues surrounding preclinical models. Discuss your experiences and observations within focus groups then share your and the other groups’ findings with the main conference. In between the formal presentations the networking carries on. Use the multiple refreshment and lunch breaks to continue your discussions in an informal relaxed atmosphere. Move from scientific discoveries into meaningful collaborations. Speed Networking Round Table Discussions Structured Networking Breaks Networking at Tumour Models London 2015
  5. 5. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK 08.00 Registration Breakfast 09.00 Chairman’s Opening Remarks Mustafa Djamgoz, Professor of Cancer Biology, Imperial College London Preclinical Modelling to Elevate All Discoveries 9.10 Identifying Responsive Patient Populations in the Preclinic: Adopting Clinically-Relevant Models Across Oncology Therapeutics • Developing CDX and PDX modelling for breast and prostate cancer for enhanced translational success • How to satisfy the demand for clinically relevant models for understanding   disease progression Andrew McKenzie, Director, Scientific Operations, Crown Bioscience 9.40 Predictive Value of Preclinical In Vitro and In Vivo Models • Hear examples of predictability of cell based and in vivo models • Learn about the current limitations and pitfalls using CDX, PDX and syngeneic in vivo models • Discover how organoids are an emerging technology at the transition of cell based and in vivo models Jürgen Moll, Director Pharmacology Translational Research, Boehringer-Ingelheim 10.10 Morning Refreshments Speed Networking Modelling the Next Wave of Immunotherapies 11.10 Modelling Efficacy of Cancer Immunotherapies • Clinical entrance de-risking strategies for immunotherapy platforms • Discuss lessons learnt from modelling antibody dependent cell cytotoxicity immunotherapies • How to develop preclinical strategies to further enhance the development of immunotherapies Christian Gerdes, Head of Pharmacology, Roche  Pharma Research Early Development , Roche Innovation Center Zürich 11.40 Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics • Learn how the use of NSGTM mouse, JAX® In Vivo Pharmacology Services has combined the human CD34+ hematopoietic stem cell engrafted NSG with human patient derived xenograft to create a platform for humanized preclinical studies in immuno-oncology • Find out how this platform has been used to evaluate immune checkpoint inhibitors such as Keytruda • Address how we are evaluating NSG-SGM3 mice for humanization and co- engraftment of PDX, as these mice express human IL-3, GM-CSF, and KIT ligand, that allow improved development of regulatory T cells and myeloid cells • Discover how several PDX tumours have been successfully engrafted in the hu- CD34 NSG-SGM3 hosts, enabling further research into both the basic biology and development of therapeutics in human immuno-oncology Brian Soper, Technical Information Scientist, The Jackson Laboratory 12.10 Immunologically-Relevant Tumour Models to Interrogate Antibody Efficacy and to Bridge the Translational Gap • Interrogating direct mechanisms of action and effector functions and efficacy of anti-tumour antibodies by employing a combination of tailored in vitro and in vivo evaluations • Design of cancer models relevant to antibody biology, human immunity and human malignant disease to interrogate antibody efficacy and safety • Translating antibodies of different classes/subclasses through interrogating humanized, PDX and surrogate in vivo models Sophia Karagiannis, Senior Lecturer in Translational Cancer Immunology, Head of Cancer Antibody Discovery Immunotherapy, King’s College London Conference Day One Wednesday 2nd December 2015
  6. 6. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK 4.40 Chair’s Closing Remarks Mustafa Djamgoz, Professor of Cancer Biology, Imperial College London 5.00 Drinks Reception Hosted by Crown Bioscience Maximise the use of in vivo and in vitro models to better predict drug-related toxicities at the preclinical stage, detect adverse events and avoid costly mistakes in the clinic 4. 12.40 Networking Lunch Microenvironment Combination Cancer Therapies 1.40 Combinations of Targeted Therapies with Radiotherapy: The Dbait Repair Inhibitors to Fight Resistance • Challenges of pre-clinic studies with radiotherapy: The need of dedicated platforms • Safety issues: Planned combinations versus incidental associations • Discover how to address radiosensitizers • The repair inhibitor Dbait: Using an agonist to disable all DNA repair pathways • From bench-to-bedside. What did we learn? Marie Dutreix, Director of Research, Institut Curie 2.10 Driving Early Phase Combinations in the UK • The Combinations Alliance is a joint initiative between the Cancer Research UK Centre for Drug Development (CDD), the Experimental Cancer Medicines Centre network (ECMC) and industry collaborators • Identify and deliver the best early phase combination trials to maximise treatment options for people with cancer by driving forward industry and academia collaborations • Learn about how these collaborations will bring together strengths from both fields, in particular using the academic expertise to ensure the correct animal models are used for preclinical work • Explore the CRUK funding available to build preclinical evidence to support the progression of novel drug combinations into early phase trials, including radiotherapy-drug combinations Julie Stock, Preclinical RaDCom Project Manager, Cancer Research UK 2.40 Targeting Tumour Metabolism to Eradicate Cancer Stem Cells: In Vitro and In Vivo Models of Tumourigenesis • Disease models and target biology: How to relate cancer biology to   preclinical models • How can we truly understand the metastatic microenvironment? • Discuss models that accurately recapitulate human tumour biology at the level of morphology, heterogeneity and genomics Michael Lisanti, Director, Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester 3.10 Afternoon Refreshments Poster Session 3.40 Breakout Roundtables: Bridging the Gap Between Discovery and the Clinic Improving the understanding of your immunotherapies: Lessons learned and data generated from syngeneic models, humanized models and ex vivo approaches Sukhvinder Sidhu, Head of Pharmacology, Oncology Drug Discovery Preclinical Development, Sanofi 1. Preclinical Phase II Trials - How to effectively run coupled/co-clinical trials? 2. Advancing tumour models that physiologically represent the tumour microenvironment to enhance prediction of patient clinical outcomes Michael Lisanti, Director, Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester 3.
  7. 7. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK 08.00 Registration Breakfast 09.00 Chairman’s Opening Remarks Mustafa Djamgoz, Professor of Cancer Biology, Imperial College London Translational Research: Personalised Models for Personalised Medicines 9.10 Selecting Preclinical Models for Immunotherapy • Immunotherapy is an emerging field in oncology and different preclinical systems are required compared to tumour therapies • Refine in vivo model selection more effectively by following comprehensive profiling of the model • Understand the immune context of the tumour allows response hypotheses to be built based on immunological criteria • Link mouse model data to human clinical sample analysis to allow hypotheses to be further refined to guide translational and clinical strategy Kelli Ryan, Senior Scientist, MedImmune 9.40 PDX-Directed Programs for Clinical Advancement • A PDX platform where patient tumours are engrafted to form models for predictive personalised treatment testing • Address the therapeutic treatment responses in the PDX being used prospectively to guide patient treatment and responses • Learn to design downstream predictive treatment algorithms using biomarker data analysed to ascertain signatures of molecular response • PDX resources for conducting efficient high-throughput translational medicine screens across multitudes of models Neal Goodwin, VP, Corporate Research Development, Champions Oncology 10.10 Drug Repurposing for the Development of Novel Cancer Therapies • Characterisation of novel mechanisms operating in cancer to form the bases of targeted therapies which, in part, can be made possible by ‘repurposing’ drugs from other fields of medicine • Targeting metastasis with anti-epileptic and anti-anginal drugs, which have been shown to be anti-invasive in vivo Mustafa Djamgoz, Professor of Cancer Biology, Imperial College London 10.40 Morning Refreshments Optimal Predictors of Clinical Outcomes 11.10 Naturally Occurring Canine Cancer as a Translational Model for Novel Anti-Cancer Therapies • What comparative oncology tells us about the interests of spontaneous canine tumours as models for cancer research • An example of clinical pharmacology study in naturally occurring canine lymphoma • How this model could be useful for translational studies of new immunotherapies Bruno Gomes, Senior Project Leader, Society, iTeos Therapeutics 11.40 Use of Patient-Derived Material in Translational Research to Support Drug Development in Oncology  Highlighting the following: • In vitro tumour colony formation assays using PDX for indication screening • Ex vivo explants from fresh tumour biopsies to investigate drug combinations • In vivo mouse trials: Study design, data interpretation and translation to the clinics Anne Chessex, Senior Scientific Officer, Pharmacology Screening, Debiopharm Conference Day Two Thursday 3rd December 2015
  8. 8. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK 12.10 Identification of Potential Biomarkers to Predict Therapeutic Efficacy to Drive Preclinical to Clinical Translation • Preclinical identification of predictive biomarkers for cancer treatment • Learn to identify biomarkers for patient stratification and molecular signatures of drug response • Use PDX models as predictive tools to prepare clinical trials Christoph Schatz, Senior Scientist, Bayer Healthcare 1.10 Networking Lunch 2.10 Development of Preclinical Models in Radioimmunotherapy • Radioimmunoconjugate therapy: Working with radioactivity in preclinical   cancer models • Highlighting specific problems with using immune compromised mice for radioimmunotherapy studies • How to measure toxicity and efficacy of radioimmunotherapy in mouse models? Adam O’Shea, Scientist, Nordic Nanovector ASA 2.40 The Analysis of Drug Combinations in Tumour Models • Identify combination benefits through mathematical modelling • Use mathematical models of synergy to develop potential combination therapies • Evaluate the combinations’ toxicity vs. efficacy to improve clinical outcomes Giovanni Di Veroli, Associate Director of Systems Pharmacology, AstraZeneca 3.10 Afternoon Refreshments Novel Models to Accurately Guide Next Generation Cancer Therapies 3.40 Panel Discussion: Highlight Cutting Edge Advances in In Vivo, In Vitro and In Silico Modelling to Facilitate a Discussion About Effective Translational Approaches in Cancer Research • Can preclinical models predict the results of phase 3 clinical trials? • What toolkit of models does a preclinical research need to harness, when should they use them and when should they invest? • Best practice for implementing novel strategies of preclinical cancer research • Innovative in vitro models for minimising preclinical mistakes and ultimately   clinical failures • How to effectively evaluate novel cancer therapeutics as well as to identify predictive biomarkers in early stages of drug development Moderator: Mustafa Djamgoz, Professor of Cancer Biology, Imperial College London Sukhvinder Sidhu, Head of Pharmacology, Oncology Drug Discovery Preclinical Development, Sanofi Michael Lisanti, Director, Manchester Breakthrough Breast Cancer Research Unit, University of Manchester 4.10 Chairman’s Closing Remarks Mustafa Djamgoz, Professor of Cancer Biology, Imperial College London 4.15 Close of Tumour Models London 2015 Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues Past Tumour Models London attendee, Sanofi Aventis
  9. 9. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK Partners Crown Bioscience Crown Bioscience provides Translational Platforms focused on fast-tracking candidates to identify biomarkers and patient responders based on the pharmacological response of human surrogate models. Power your Drug Discovery using the world’s largest commercial collection of well-characterised PDX in passage (HuPrime) plus a curated, searchable database of patient, genotypic and phenotypic data as well as pharmacological response (HuBase). Identify potential biomarkers (HuSignature™) based on pharmacological response or use your biomarker signature to identify models available for screening to confirm patient responder and non- responder populations (HuTrials™). Fast forward your drug discovery programs today. www.crownbio.com Champions Oncology Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar model for growing and testing human tumours. Champions Personalized TumorGrafts™ empower patients and physicians using an in vivo xenograft mouse avatar based diagnostic model that has shown to be predictive of a patients’ clinical response to cancer treatments and anticancer therapies. www.championsoncology.com The Jackson Laboratory The Jackson Laboratory is an independent, nonprofit biomedical research institution and a National Cancer Institute-designated Cancer Center. Founded in 1929, the Laboratory applies its eight decades of expertise in genetics to increase understanding of human disease, advancing treatments and cures for cancer, neurological and immune disorders, diabetes, aging and heart disease. It models and interprets genomic complexity, integrates basic research with clinical application, educates current and future scientists, and empowers the global biomedical community by providing critical data, tools and services. www.jax.org Harlan Laboratories Harlan Laboratories is a leading global provider of research models and services to the worldwide Pharmaceutical, Biotech, Contract Research and Academic/Government sectors. Global availability of high quality nude mice, SCID mice, nude rats and general purpose models for your area of oncology research with proven performance in tumour update and growth. www.harlan.com Tumour Models London 2015 is proud to partner with the following industry pioneers: Lead Partner Program Partner Program Partner Exhibitor Become a Tumour Models Commercial Partner Diane McKenna Commercial Director Tel: +44 (0)203 141 8700 Email: sponsor@hansonwade.com
  10. 10. Tel: +44 (0)203 141 8700 Email: info@hansonwade.com www.tumour-models.com Tumor Models @Tumor_Models Tumour Models London | 1-3 December 2015, London, UK Code:5156 * All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation. Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time. Changes to Conference Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU Hanson Wade Limited. Registered in England Wales. Company No: 6752216 Terms Conditions Register Event Prices Pricing Venue Hilton London Olympia Hotel 380 Kensington High St, London W14 8NL Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering. www.tumour-models.com/register Tel: +44 (0)203 141 8700  Email: register@hansonwade.com Mail: Hanson Wade  4th Floor, 52 Grosvenor Gardens,   London, SW1W 0AU • 10% discount – 3 delegates  • 15% discount – 4 delegates  • 20% discount – 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Team Discounts* Industry Pricing Package Register Pay before 9th October 2015 Register Pay before 6th November 2015 Standard Prices Conference + Workshop £2098 + VAT (save £500) £2298 + VAT (save £300) £2498 + VAT (save £100) Conference Only £1599 + VAT (save £400) £1799 + VAT (save £200) £1999 + VAT Workshop Only £599 + VAT Academic Not-For-Profit Pricing Package Register Pay before 9th October 2015 Register Pay before 6th November 2015 Standard Prices Conference + Workshop £1258.80 + VAT £1378.80 + VAT £1498.90 + VAT Conference Only £959.40 + VAT £1079.40 + VAT £1498.90 + VAT Workshop Only £359.40 + VAT Full payment is due on registration. VAT is charged at 20%

×